

Current report according to CNVM Statute No 1/ 2006

Report date	9.04.2014
Name of issuer	Farmaceutica REMEDIA
Headquarters	Deva, str. Dorobantilor nr.43
Tel/ fax no	0254 22 32 60 / 0254 22 61 97
ORC no	J20/700/1991
Unic Registration Code	2115198
Subscribed and paid capital	10.608.980 RON
Regulated market	BVB

Important events to report:

Esteemed Investors,

We inform you that the ORDINARY GENERAL MEETING OF SHAREHOLDERS of Farmaceutica REMEDIA took place on 9.04.2014.

The shareholders registered in the Register of the Shareholders at the date of 31.03.2014 participated to the meeting. Out of the total of 106.089.800 issued shares, the shareholders having 78.798.112 shares have been present to the meeting, representing 74,27% out of the social capital. After the debating the points on the agenda, the ORDINARY GENERAL MEETING OF SHAREHOLDERS of Farmaceutica REMEDIA adopted the Decision no.57 of April 9th, 2014, as below:

DECISION NO. 57 OF APRIL 9, 2014
of the ORDINARY GENERAL MEETING OF SHAREHOLDERS
of Farmaceutica REMEDIA S.A.
J20/700/1991, CUI RO 2115198

Adopted today, 9.04.2014, at the secondary office of the company in Bucharest, 78 Metalurgiei Blvd., District 4. After debating the points on the agenda, the Ordinary General Meeting of Shareholders decides as follows:

1. The Ordinary General Meeting of Shareholders (OGMS) approves unanimously the consolidation of the business by transfer through sale to Farmaceutica REMEDIA S.A. of the goodwill of the majority-owned companies, recognizes the representativeness of the non-consolidated financial statements for 2013 and approves them based on the reports submitted by the Chairman of the Board of Directors and the financial auditor, with the following representative figures:

Name of indicator	Values at 31.12.2013 (RON)
Fixed assets - TOTAL	37,829,409
Current assets - TOTAL	121,536,274
TOTAL short-term liabilities	116,964,092
TOTAL long-term liabilities	1,709,629
Provisions	397,856
Net turnover	237,835,524
Operating income - TOTAL	239,029,370
Operating expenses - TOTAL	235,419,461
Financial income - TOTAL	939,129
Financial expenses - TOTAL	1,087,199
TOTAL INCOME	239,968,499
TOTAL EXPENSES	236,506,660
Tax	448,465
NET PROFIT	3,013,374

2. The Ordinary General Meeting of Shareholders approves unanimously the discharge of directors for 2013.
3. The Ordinary General Meeting of Shareholders approves, by majority vote, the revenue and expenditure budget of **Farmaceutica REMEDIA S.A.** for 2014, with the following representative figures:

Name of indicator	Value (RON)
TOTAL REVENUES, of which:	262,738,990
Net income from sales of goods	258,514,000
Other income	3,285,730
Financial income	300,000
Income from provisions	639,260
TOTAL COSTS, of which:	259,312,880
Net cost of goods sold	222,202,643
Other costs	35,574,237
Financial costs	66,000
Depreciation and provisions	1,470,000
GROSS PROFIT	3,426,110

4. The Ordinary General Meeting of Shareholders approves unanimously the **2014 investment program** totaling proposed investments amounting to **RON 1,968,200.**

5. The Ordinary General Meeting of Shareholders approves unanimously the proposal of the Board of Directors regarding the allocation of the net profit achieved in the financial year 2013 for various designations, the establishment of the gross dividend per share, of the deadline and the methods of payment of dividends to shareholders as follows:

DESIGNATION	AMOUNT (RON)	SHARE OF NET PROFIT (%)

Dividends	1,591,347	52.81
Other reserves - sources available to the company for granting bonuses to employees	250,000	8.30
Other reserves – own financing sources constituted from profit	1,018,740	33.80
Legal reserves	153,287	5.09
TOTAL NET PROFIT REALIZED/DISTRIBUTED	3,013,374	100.00

6. The Ordinary General Meeting of Shareholders approves the proposal of the Board of Directors for fixing the gross dividend per share, the payment interval, the assumption of the distribution costs and the dividend distribution procedure as follows:

- a) unanimously **fixes the gross dividend per share at RON 0.015**, which represents a distribution rate of 52.81% of the total net profit achieved in the fiscal year 2013;
- b) unanimously decides the **time of payment**/release of dividends from the 2013 profit to shareholders is 1.08 – 09.10.2014;
- c) unanimously, **the distribution costs for dividends are paid by Farmaceutica REMEDIA S.A.;**
- d) unanimously **delegates** to the Board of Directors the competence of establishing the **dividend distribution procedure.**

7. The Ordinary General Meeting of Shareholders approves, by majority vote, the **remuneration and other benefits** for the members of the Board of Directors and the maximum limit up to which additional remunerations can be granted for the Directors with mandate agreement and other managers between 10.04.2014 and 30.04.2015 as follows:

- The compensation of the Board of Directors and the General Manager shall be limited to a maximum of RON 50,000 net monthly.
- The additional allowance is limited to 17.5% of net profit after approval of the annual financial statements (amount that includes all taxes).

8. The Ordinary General Meeting of Shareholders approves unanimously the **date of 29.04.2014 as the registration date** in accordance with the provisions of Article 238 paragraph 1 of Law 297/2004 on the capital market.

9. The Ordinary General Meeting of Shareholders approves unanimously the **authorization of "TARUS" – Valentin Norbert TARUS e.U.**, Chairman of the Board of Directors, represented by Mr. Valentin-Norbert TARUS, to sign all documents issued following the Ordinary General Meeting of Shareholders.

President of the Ordinary General Meeting of Shareholders

Secretary of the Ordinary General Meeting of Shareholders